ArticleNPJ Parkinson's disease2024

Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.

Michel Alexander SteinerPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.